Glaxo to publish more trial data

Drugmaker GlaxoSmithKline, which paid $3bn (£1.9bn) last year to settle charges that it gave misleading information on its medicines, said yesterday it would publish more of its clinical research data. When the company agreed to the fines last July, government officials called it the largest healthcare fraud case in US history, involving Glaxo drugs such as the antidepressant Paxil and diabetes pill Avandia.